Chinese regulators approved Celgene's Revlimid, or lenalidomide, to treat relapsed or refractory multiple myeloma. The treatment's launch in China is expected in the next quarter.
Celgene's cancer drug Revlimid obtains Chinese approval
SmartBrief Job Listings for Health Care
|Sr. Medical Device Reimbursement Specialist - Regional||
|Fort Worth , TX|
|Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group||
|Clinical Trials Agreements Specialist (209955)||
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
|SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST||
Matheson Tri-Gas, Inc.
ASAHI INTECC, Orange County CA R&D Center
|Santa Ana, CA|